Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Barnes TA, O’Kane GM, Vincent MD, et al. Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. Front Oncol. 2017;7:113. https://doi.org/10.3389/fonc.2017.00113 .

Choo JR, Tan C-S, Soo RA. Treatment of EGFR T790M-positive non-small cell lung cancer. Targ Oncol. 2018;13:141–56.

Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018;17(1):29.

Lamb YN, Scott LJ. Osimertinib: a review in T790M-positive advanced non-small cell lung cancer. Targ Oncol. 2017;12(4):555–62.

Tagrisso (osimertinib) 40 and 80 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2018.

Tagrisso® (osimertinib) tablets, for oral use: US prescribing Information. Wilmington: Astra Zeneca Pharmacueticals LP; 2018.

Liam CK. Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer. Transl Lung Cancer Res. 2017;6(Suppl 1):S62–6.

Jeong BH, Um SW. First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. Ann Transl Med. 2018;6(3):62. https://doi.org/10.21037/atm.2017.12.30 .

Wang S, Song Y, Yan F, et al. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med. 2016;10(4):383–8.

Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol. 2018;10:1–12.

Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.

Planchard D, Boyer M, Lee JS, et al. Osimertinib vs standard of care (SOC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes [abstract no. 128O]. J Thorac Oncol. 2018;13(4 Suppl):S72–3.

Vansteenkiste J, Reungwetwattana T, Nakagawa K, et al. CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutations (EGFRm)-postive advanced non-small cell lung cancer (NSCLC): data from the FLAURA study [abstract]. In: European Society of Medical Oncology—Asia Conference. 2017.

Leighl N, Karaseva N, Nakagawa K, et al. Patient-reported outcomes from FLAURA: osimertinib versus standard of care (SOC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSLC) [abstract no. 139PD]. J Thorac Oncol. 2018;13(4 Suppl):S81–S82.

Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(9):841–9.

Sun JM, Park K. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? Curr Opin Oncol. 2017;29(2):89–96.

National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): non-small cell lung cancer (version 1.2018). Fort Washington: National Comprehensive Cancer Network®, Inc; 2017.

Novello S, Barlesi F, Califano R, et al. Metastatic non small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v1–27.

Summary of opinion (post authorization): Tagrisso (osimertinib). London: European Medicines Agency; 2018.

US National Institutes of Health. Osimertinib treatment on EGFR T790M plasma positive NSCLC patients (APPLE) [NCT02856893]. https://clinicaltrials.gov/ct2/show/NCT02856893 . Accessed 3 July 2018.